Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jan;39(1):21-4.
doi: 10.1097/OLQ.0b013e31823b50c6.

Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial

Jared M Baeten  1 , Stewart E Reid, Sinead Delany-Moretlwe, James P Hughes, Richard S Wang, Ellen Wilcox, Mohammed Limbada, Godspower Akpomiemie, Lawrence Corey, Anna Wald, Connie Celum
Affiliations
Randomized Controlled Trial

Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial

Jared M Baeten et al. Sex Transm Dis. 2012 Jan.

Abstract

In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

LC has received consulting fees from AiCuris, which is developing treatments for HSV and cytomegalovirus infections, is listed as a coinventor on several patents describing antigens and epitopes to which T-cell responses to HSV-2 are directed (these proteins have the potential to be used in candidate vaccines against HSV), and has received fees for serving as the head of the scientific advisory board of Immune Design, including equity shares that are less than 1% ownership. AW has received consulting fees from AiCuris. AW and CC have received research grant support from GlaxoSmithKline. All other authors declare they have no known conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves, with log-rank p-values, and time-to-event analyses, for a) primary (time to healing of all genital lesions) and b) secondary (time to first negative HSV DNA PCR) study endpoints.
Figure 1
Figure 1
Kaplan-Meier survival curves, with log-rank p-values, and time-to-event analyses, for a) primary (time to healing of all genital lesions) and b) secondary (time to first negative HSV DNA PCR) study endpoints.
See this image and copyright information in PMC

Comment in

References

    1. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83. - PubMed
    1. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560–71. - PMC - PubMed
    1. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–19. - PMC - PubMed
    1. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190:1374–81. - PubMed
    1. Fuchs J, Celum C, Wang J, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis. 2010;201:1164–8. - PMC - PubMed

Publication types

MeSH terms

Associated data